<DOC>
	<DOC>NCT00144547</DOC>
	<brief_summary>This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA012JP.</brief_summary>
	<brief_title>Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Inclusion criteria Patients must suffer from RA, and must have participated in the preceding study. Patients must have been confirmed to be appropriate on week 52 of the preceding study by X radiography. Exclusion criteria Patients evaluated as belonging to Steinbrocker's class IV within 4 weeks before administration of the study drug Patients who have not been registered by 3 months after week 52 of the preceding study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>